항암화학요법의 구토유발 수준별 예방적 항구토제 프로토콜의 이행정도
Compliance with the Protocol Considered Emetogenic Potential for Prophylaxis of Chemotherapy Induced Nausea and Vomiting
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
본 연구 결과, 일반적 및 질병관련 특성에 따른 급성 오심 · 구토 정도는 임신 시 입덧을 경험한 경우와 예측성 오심을 경험한 경우에 높았다. 항암제의 구토유발 수준별 급성 오심·구토 정도는 3일째에 항암제의 구토유발 수준이 낮은 경우가 높은 경우보다 높았으며, 예방적 항구토제에 관한 프로토콜 이행 정도는 항암제 구토유발 수준에 따라 차이가 있었다. 그러나 예방적 항구토제 프로토콜의 이행 정도에 따른 1일부터 3일째 급성 오심 · 구토 정도에는 차이가 없었다. 결론적으로 항암제의 구토유발 수준에 따른 예방적 항구토제 프로토콜의 이행은 대체적으로 잘 이루어지고 있다고 판단되며, 입덧을 경험했거나 예기성 오심이 있는 경우에는 급성 오심 · 구토를 감소시키기 위해 보다 적극적인 예방적 항구토제 사용을 권하고, 종양전문 간호사는 대상자에게 투여되고 있는 항암제의 구토유발 수준보다는 대상자의 오심 · 구토 증상호소에 더 민감할 필요가 있다.
Abstract
Purpose: The purpose of this study was to identify the compliance with the protocol, which was developed considering the emetogenic potential for prophylaxis of chemotherapy. Methods: Data was collected from 144 patients who received chemotherapy from June 15 to August 31, 2010 in C University Hospital in Jeollanamdo, Korea. The level of chemotherapy-induced nausea and vomiting (CINV) and the compliance with the protocol for prophylaxis of CINV were measured. Results: There was statistically significant difference of CINV in morning sickness and anticipatory nausea of general and clinical characteristics. Also, the compliance with the protocol developed according to emetogenic potential of chemotherapy was statistically significant. There was no difference in CINV in regard to the compliance with the protocol. Conclusion: There was a good compliance with the protocol for prophylaxis according to emetogenic potential. But it should be recommended to use antiemetics for prophylaxis aggressively to relieve CINV for the patients who already experienced morning sickness and anticipatory nausea. In addition, the oncology nurses should respond sensitively to the complaints of nausea and vomiting no matter what the emetogenic potentials of chemotherapy regimen are.
참고문헌 (24)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality and Survival in 2006-2007", Journal of Korean Medical Science, 25(8), pp.1113~1121 (2010), 대한의학회
- Jordan K, "Guidelines for antiemetic treatment of chemotherapy induced nausea and vomiting: past. present, future recommendations", The Oncologist, 12, pp.1143~1150 (2007)
- Oh CY, "Evaluation of antiemetic therapy after the administration of high-dose antineoplastic agents: Focused Ondansetron", J Kor Soc Hosp Pharm, 16, pp.495~500 (1999)
- 손영수, "저출산 국가위기의 대처 방안", 한국위기관리논집, 2(1), pp.30~35 (2006), 위기관리 이론과 실천
- Kris MG, "American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006", J Clin Oncol, 24, pp.2932~2947 (2006)
- Hesketh PJ, "Proposal for classifying the acute emetogenicity of cancer chemotherapy", J Clin Oncol, 15, pp.103~109 (1997)
- Kris MG, "American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006", J Clin Oncol, 24, pp.2932~2947 (2006)
- Multinational Association of Supportive Care in Cancer, "Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)", Ann Oncol, 9, pp.811~819 (1998)
- Gralla RJ, "Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology", J Clin Oncol, 17, pp.2971~2994 (1999)
- European Society for Medical Oncology, "ESMO recommendations for prophylaxis of chemotherapy-induced nauseaand vomiting (NV)", Ann Oncol, 12(8), pp.1059~1060 (2001)
- National Comprehensive Cancer Network, "Effective interventions for CINV: NCCN Antiemesis Clinical Practice Guidelines in Oncology", ONS News, 19(9), pp.17~18 (2004)
- Herrstedt J, "Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis", Ann Oncol, 19(2), pp.110~112 (2008)
- Asan Medical Center Cancer Center, "Clinical practice guideline for Chemotherapy" (2009), Koonja publishers
- Wickham R, "Best practice management of CINV in oncology patient: II. Antiemetic guideline and retionale for use", J Support Oncology, 8(2), pp.10~15 (2010)
- Shih V, "Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide", Ann Pharmacother, 43, pp.444~452 (2009)
- Warr DG, "Chemotherapy-and cancer-related nausea and vomiting", Curr Oncol, 15(1), pp.4~9 (2008)
- Mertens WC, "Improving the care of patients with regard to chemotherapy induced nasuea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines", J Clin Oncol, 21, pp.1373~1378 (2003)
- Rhodes VA, "Criteria for assessment of nausea, vomiting, and retching", Oncol Nurs Forum, 24(7), pp.13~19 (1997)
- Rhodes VA, "The index of nausea, vomiting and retching: a new format of the Index of Nausea and Vomiting", Oncol Nurs Forum, 26, pp.889~894 (1999)
- Kim YJ, "The index of nausea, vomiting and retching(Korean translation)", J Korean Acad Adult Nurs, 12, pp.278~285 (2000)
- Molassiotis A, "Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients", Support Care cancer, 10, pp.139~145 (2001)
- "Use of antiemtics in the management of chemotherapy-related nausea and vomiting in current UK practice. Support Care Cancer"[URL]
- Heffinger AI, "The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers", Ann Oncol, 15, pp.526~536 (2004)
- Grélot L, "Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist", Br J Pharmacol, 124, pp.1643~1650 (1998)